Utah Valley Hospital
- Type
- Teaching hospital
- Where
- Provo, UT
- Medicare CCN
- 460001
- Received
- $899,885 in 100 records, 2021 ($40,794 general, $859,090 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 25 | $40,794 |
| 2021 | Research payment | 75 | $859,090 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Gilead Sciences, Inc. | 22 | $372,517 | 2021 |
| Siemens Medical Solutions USA, Inc. | 3 | $235,549 | 2021 |
| Abbott Laboratories | 40 | $133,796 | 2021 |
| Amgen Inc. | 3 | $68,907 | 2021 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33,333 | 2021 |
| ONY Biotech Inc. | 7 | $31,000 | 2021 |
| AstraZeneca Pharmaceuticals LP | 2 | $10,915 | 2021 |
| Boston Scientific Corporation | 6 | $5,179 | 2021 |
| Cochlear Americas | 2 | $2,294 | 2021 |
| United Therapeutics Corporation | 1 | $2,000 | 2021 |
| KLS-Martin L.P. | 1 | $2,000 | 2021 |
| Baxter Healthcare | 1 | $750 | 2021 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $750 | 2021 |
| Cadwell Industries, INC | 1 | $350 | 2021 |
| Linvatec Corporation | 1 | $261 | 2021 |
| Apria Healthcare LLC | 7 | $179 | 2021 |
| Stryker Corporation | 1 | $101 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 75 | $859,090 |
| Grant | 1 | $33,333 |
| Space rental or facility fees (teaching hospital only) | 4 | $3,659 |
| Long term medical supply or device loan | 4 | $2,657 |
| Consulting Fee | 1 | $500 |
| Education | 1 | $350 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 7 | $179 |
| Food and Beverage | 7 | $115 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $118,615 | Research payment | Cash or cash equivalent | Medicalis workflow orchestration integration | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $112,686 | Research payment | Cash or cash equivalent | Enterprise reading and reporting investigation | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $4,248 | Research payment | Cash or cash equivalent | ACUSON Sequoia Diagnostic Ultrasound System Device, US - Ultrasound Systems | Ultrasound ARFI Cervical Assessment of Preterm Delivery | 2021 |
| 2021-12-31 | Linvatec Corporation | $261 | Long term medical supply or device loan | In-kind items and services | MICROPOWER Device, ORTHOPEDIC SURGERY | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $249 | Research payment | In-kind items and services | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2021 | |
| 2021-12-22 | Gilead Sciences, Inc. | $16,000 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semagl | 2021 | |
| 2021-12-22 | Gilead Sciences, Inc. | $1,390 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-12-20 | ONY Biotech Inc. | $2,000 | Research payment | Cash or cash equivalent | Infasurf Drug, Respirology | AERO-03 | 2021 |
| 2021-12-13 | Abbott Laboratories | $240 | Research payment | In-kind items and services | Device, Structural Heart | TRILUMINATE Pivotal | 2021 |
| 2021-12-06 | Boston Scientific Corporation | $2,450 | Research payment | Cash or cash equivalent | Watchman Device, Structural Heart | OPTION | 2021 |
| 2021-12-06 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | Watchman Device, Structural Heart | OPTION | 2021 |
| 2021-12-03 | ONY Biotech Inc. | $500 | Research payment | Cash or cash equivalent | Infasurf Drug, Respirology | AERO-03 | 2021 |
| 2021-12-01 | Abbott Laboratories | $210 | Research payment | In-kind items and services | MitraClip System Device, Structural Heart | REPAIR MR IDE Study | 2021 |
| 2021-11-24 | Abbott Laboratories | $6,361 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Ca | 2021 |
| 2021-11-19 | Cadwell Industries, INC | $350 | Education | Cash or cash equivalent | Sierra Summit Device, Electrodiagnostic | 2021 | |
| 2021-11-18 | ONY Biotech Inc. | $9,500 | Research payment | Cash or cash equivalent | Infasurf Drug, Respirology | AERO-03 | 2021 |
| 2021-11-17 | Gilead Sciences, Inc. | $13,445 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-11-17 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | MitraClip System Device, Structural Heart | 2021 | |
| 2021-11-17 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | MitraClip System Device, Structural Heart | 2021 | |
| 2021-11-17 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | MitraClip System Device, Structural Heart | 2021 | |
| 2021-11-17 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | MitraClip System Device, Structural Heart | 2021 | |
| 2021-11-17 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | MitraClip System Device, Structural Heart | 2021 | |
| 2021-11-17 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | MitraClip System Device, Structural Heart | 2021 | |
| 2021-11-17 | Abbott Laboratories | $16 | Food and Beverage | In-kind items and services | MitraClip System Device, Structural Heart | 2021 | |
| 2021-11-10 | Abbott Laboratories | $36,411 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2021 |
| 2021-10-27 | United Therapeutics Corporation | $2,000 | Research payment | Cash or cash equivalent | AN OPEN-LABEL EXTENSION STUDY OF APD811 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION | 2021 | |
| 2021-10-20 | Gilead Sciences, Inc. | $4,941 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-10-20 | Gilead Sciences, Inc. | $1,751 | Research payment | Cash or cash equivalent | Harvoni Drug, HCV | A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for H | 2021 |
| 2021-10-18 | Boston Scientific Corporation | $1,226 | Research payment | Cash or cash equivalent | Watchman Device, Structural Heart | OPTION | 2021 |
| 2021-10-05 | Gilead Sciences, Inc. | $16,649 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-10-05 | Gilead Sciences, Inc. | $14,790 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-10-05 | Gilead Sciences, Inc. | $12,891 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-10-05 | Gilead Sciences, Inc. | $9,893 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-10-05 | Gilead Sciences, Inc. | $5,253 | Research payment | Cash or cash equivalent | Harvoni Drug, HCV | A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for H | 2021 |
| 2021-10-05 | Gilead Sciences, Inc. | $5,049 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-10-05 | Gilead Sciences, Inc. | $2,542 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-10-05 | Gilead Sciences, Inc. | $900 | Research payment | Cash or cash equivalent | Harvoni Drug, HCV | A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for H | 2021 |
| 2021-09-22 | Gilead Sciences, Inc. | $4,496 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-09-16 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-09-01 | Abbott Laboratories | $22,088 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2021 |
| 2021-09-01 | Apria Healthcare LLC | $15 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-08-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-08-25 | Abbott Laboratories | $700 | Research payment | Cash or cash equivalent | MitraClip System Device, Structural Heart | COAPT Study | 2021 |
| 2021-08-18 | Abbott Laboratories | $1,191 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-08-16 | Gilead Sciences, Inc. | $42,500 | Research payment | Cash or cash equivalent | COVID-19 Acute and Long Term Experience Diary (.ALTrED) | 2021 | |
| 2021-08-16 | Stryker Corporation | $101 | Long term medical supply or device loan | In-kind items and services | SURGICOUNT Device, SURGICAL | 2021 | |
| 2021-08-11 | Abbott Laboratories | $7,781 | Research payment | Cash or cash equivalent | MitraClip System Device, Structural Heart | Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Ca | 2021 |
| 2021-08-11 | Abbott Laboratories | $85 | Research payment | Cash or cash equivalent | Dragonfly OCT Device, Vascular | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2021 |
| 2021-08-10 | Abbott Laboratories | $1,130 | Research payment | In-kind items and services | FreeStyle Lite system Device, Diabetes Care | Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | 2021 |
| 2021-08-10 | Abbott Laboratories | $208 | Research payment | In-kind items and services | FreeStyle Lite system Device, Diabetes Care | Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | 2021 |
| 2021-08-04 | ONY Biotech Inc. | $8,500 | Research payment | Cash or cash equivalent | Infasurf Drug, Respirology | AERO-03 | 2021 |
| 2021-08-04 | Abbott Laboratories | $740 | Research payment | Cash or cash equivalent | MitraClip System Device, Structural Heart | MitraClip EXPAND G4 Study | 2021 |
| 2021-08-02 | Abbott Laboratories | $169 | Research payment | In-kind items and services | FreeStyle Lite system Device, Diabetes Care | Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | 2021 |
| 2021-07-29 | Cochlear Americas | $194 | Long term medical supply or device loan | In-kind items and services | Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode Device, Implantable hearing solution | 2021 | |
| 2021-07-19 | Abbott Laboratories | $150 | Research payment | In-kind items and services | Device, Structural Heart | TRILUMINATE Pivotal | 2021 |
| 2021-06-30 | Abbott Laboratories | $2,518 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Ca | 2021 |
| 2021-06-09 | Amgen Inc. | $21,632 | Research payment | Cash or cash equivalent | STEM BONE LOSS | 2021 | |
| 2021-06-09 | Abbott Laboratories | $150 | Research payment | In-kind items and services | Device, Structural Heart | TRILUMINATE | 2021 |
| 2021-06-07 | Apria Healthcare LLC | $30 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-06-07 | Apria Healthcare LLC | $15 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-06-07 | Apria Healthcare LLC | $15 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-05-28 | Abbott Laboratories | $216 | Research payment | In-kind items and services | FreeStyle Libre Pro Device, Diabetes Care | Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | 2021 |
| 2021-05-26 | KLS-Martin L.P. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-05-20 | Boston Scientific Corporation | $267 | Research payment | Cash or cash equivalent | Watchman Device, Structural Heart | OPTION | 2021 |
| 2021-05-19 | Gilead Sciences, Inc. | $2,960 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-05-17 | Boston Scientific Corporation | $118 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | APPRAISE ATP | 2021 |
| 2021-05-12 | Abbott Laboratories | $21,257 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2021 |
| 2021-04-28 | Abbott Laboratories | $1,694 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | MitraClip EXPAND G4 Study | 2021 |
| 2021-04-27 | ONY Biotech Inc. | $6,500 | Research payment | Cash or cash equivalent | Infasurf Drug, Respirology | AERO-03 | 2021 |
| 2021-04-26 | Gilead Sciences, Inc. | $17,460 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-04-26 | Apria Healthcare LLC | $15 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-04-07 | Baxter Healthcare | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | STARLING SYSTEM Device, Fluid Systems | 2021 | |
| 2021-03-31 | Abbott Laboratories | $150 | Research payment | In-kind items and services | Device, Structural Heart | TRILUMINATE | 2021 |
| 2021-03-31 | Abbott Laboratories | $90 | Research payment | In-kind items and services | MitraClip System Device, Structural Heart | Mitraclip EXPAND G4 | 2021 |
| 2021-03-25 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of | 2021 |
| 2021-03-19 | Cochlear Americas | $2,100 | Long term medical supply or device loan | In-kind items and services | Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode Device, Implantable hearing solution | 2021 | |
| 2021-03-18 | Abbott Laboratories | $500 | Consulting Fee | Cash or cash equivalent | Alinity i Device, Core Diagnostics | 2021 | |
| 2021-03-17 | Gilead Sciences, Inc. | $91,262 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-03-15 | Amgen Inc. | $37,300 | Research payment | Cash or cash equivalent | Feasibility of Oncology Remote Monitoring (FORM) | 2021 | |
| 2021-03-15 | Boston Scientific Corporation | $118 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | APPRAISE ATP | 2021 |
| 2021-03-10 | Abbott Laboratories | $2,918 | Research payment | In-kind items and services | FreeStyle Lite system Device, Diabetes Care | Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | 2021 |
| 2021-03-10 | Abbott Laboratories | $216 | Research payment | In-kind items and services | FreeStyle Lite system Device, Diabetes Care | Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | 2021 |
| 2021-03-10 | Abbott Laboratories | $171 | Research payment | In-kind items and services | FreeStyle Lite system Device, Diabetes Care | Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | 2021 |
| 2021-03-10 | Abbott Laboratories | $169 | Research payment | In-kind items and services | FreeStyle Lite system Device, Diabetes Care | Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | 2021 |
| 2021-03-10 | Apria Healthcare LLC | $74 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-03-10 | Apria Healthcare LLC | $15 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-03-06 | Abbott Laboratories | $135 | Research payment | In-kind items and services | FreeStyle Libre Device, Diabetes Care | Diabetes Discharge Transition Continuous Glucose Monitor Study (CGM Study) | 2021 |
| 2021-02-24 | Abbott Laboratories | $18,950 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2021 |
| 2021-02-23 | ONY Biotech Inc. | $2,500 | Research payment | Cash or cash equivalent | Infasurf Drug, Respirology | AERO-03 | 2021 |
| 2021-02-17 | Gilead Sciences, Inc. | $31,018 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-02-17 | Gilead Sciences, Inc. | $14,099 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-02-17 | Amgen Inc. | $9,975 | Research payment | Cash or cash equivalent | VBP11 Feasibility of Oncology Remote Mon | 2021 | |
| 2021-02-10 | Abbott Laboratories | $4,078 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Ca | 2021 |
| 2021-02-10 | Abbott Laboratories | $1,340 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-02-04 | Abbott Laboratories | $159 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-01-26 | ONY Biotech Inc. | $1,500 | Research payment | Cash or cash equivalent | Infasurf Drug, Respirology | AERO-03 | 2021 |
| 2021-01-20 | Gilead Sciences, Inc. | $62,047 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2021 |
| 2021-01-20 | Gilead Sciences, Inc. | $1,181 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-01-13 | Actelion Pharmaceuticals US, Inc. | $33,333 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-01-12 | AstraZeneca Pharmaceuticals LP | $10,666 | Research payment | Cash or cash equivalent | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Provo, UT, county Utah County, UT, state Utah; placed by its city name.
| Measure | Place (city or town) Provo, UT | County Utah County, UT | State Utah |
|---|---|---|---|
| Population B01003 | 114,766 | 705,400 | 3,392,331 |
| Population, 2020 census P1 | 115,162 | 659,399 | 3,271,616 |
| Median age B01002 | 23.6 | 25.8 | 32.0 |
| Under 18 B01001 | 18.7% | 31.6% | 27.8% |
| 65 and over B01001 | 6.7% | 7.9% | 11.9% |
| Households B11001 | 34,022 | 203,018 | 1,124,822 |
| Foreign born B05002 | 12.5% | 8.2% | 8.9% |
| Median household income B19013 | $64,171 | $100,671 | $95,166 |
| Median family income B19113 | $73,450 | $110,986 | $109,675 |
| Per capita income B19301 | $27,822 | $37,082 | $40,873 |
| Poverty rate B17001 | 23.0% | 8.7% | 8.5% |
| Unemployment rate B23025 | 5.1% | 3.8% | 3.6% |
| Civilian labor force B23025 | 69,670 | 363,771 | 1,778,106 |
| Mean commute (minutes) B08013 | 18.4 | 22.6 | 22.1 |
| Bachelor's degree or higher B15003 | 45.2% | 44.4% | 37.7% |
| Housing units B25001 | 35,944 | 211,066 | 1,223,468 |
| Owner-occupied B25003 | 39.4% | 68.3% | 70.2% |
| Renters B25003 | 60.6% | 31.7% | 29.8% |
| Median home value B25077 | $467,200 | $538,700 | $489,400 |
| Median gross rent B25064 | $1,193 | $1,541 | $1,496 |
| White, not Hispanic B03002 | 70.8% | 77.6% | 74.7% |
| Black B03002 | 1.1% | 0.7% | 1.1% |
| Hispanic or Latino B03002 | 19.2% | 14.5% | 15.9% |
| Asian B03002 | 2.2% | 1.5% | 2.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Provo, UT.
Comments